Evidence map›Paper›PMID 31858429›Full record

Trial reportInternational journal of hematology2020

Analysis of Japanese patients from the AUGMENT phase III study of lenalidomide + rituximab (R

Koji Izutsu, Yosuke Minami, Noriko Fukuhara, Yasuhito Terui, Tatsuro Jo, Go Yamamoto, Takayuki Ishikawa, Tsutomu Kobayashi, Toru Kiguchi, Hirokazu Nagai and 5 more

Abstract readClinical Trial, Phase III
PubMed Publisher
In one paragraph

Trial report in International journal of hematology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Immunotherapy of lymphomas.The Journal of clinical investigation · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 11 institutions in 3 countries.

Koji IzutsuDepartment of Hematology, National Cancer Center Hospital, 5-1-1 Tsukji, Chou-ku, Tokyo, 104-0045, Japan. kizutsu@ncc.go.jp.ORCID http://orcid.org/0000-0002-9941-2448
Yosuke MinamiDepartment of Hematology, National Cancer Center Hospital East, Chiba, Japan.
Noriko FukuharaDepartment of Hematology and Rheumatology, Tohoku University Hospital, Sendai, Japan.
Yasuhito TeruiDepartment of Hematology Oncology, The Cancer Institute Hospital of JFCR, Tokyo, Japan.
Tatsuro JoDepartment of Hematology, Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan.
Go YamamotoDepartment of Hematology, Toranomon Hospital, Tokyo, Japan.
Takayuki IshikawaKobe City Medical Center General Hospital, Hematology, Kobe, Japan.
Tsutomu KobayashiDivision of Hematology and Oncology, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Toru KiguchiDepartment of Hematology, Chugoku Central Hospital, Fukuyama, Japan.
Hirokazu NagaiDepartment of Hematology and Oncology Research, Nagoya Medical Center, Clinical Research Center, Nagoya, Japan.
Tomoko OhtsuCelgene K.K., Tokyo, Japan.
Stacey KalambakasCelgene Corporation, Summit, NJ, USA.
Pierre FustierCelgene Corporation, Boudry, Switzerland.
Shuichi MidorikawaCelgene K.K., Tokyo, Japan.
Kensei TobinaiDepartment of Hematology, National Cancer Center Hospital, 5-1-1 Tsukji, Chou-ku, Tokyo, 104-0045, Japan.
Bristol-Myers Squibb (Switzerland) · CHChugoku Central Hospital · JPJapanese Red Cross Society, Japan · JPKobe City Medical Center General Hospital · JPKyoto Prefectural University of Medicine · JPNagoya Medical Center · JPNational Cancer Center Hospital East · JPNational Cancer Centre Japan · JPThe Cancer Institute Hospital · JPTohoku University Hospital · JPToranomon Hospital · JP

Funding

Celgene N/A
6 · The paper itself

Abstract

Patients with indolent non-Hodgkin lymphoma (iNHL) typically respond to first-line immunochemotherapy, but relapse is common. Treatment options for relapsed iNHL include chemotherapy ± rituximab and rituximab monotherapy. Lenalidomide plus rituximab (R

Indexed as

AdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsDouble-Blind MethodFemaleHumansLenalidomideLymphoma, Non-HodgkinMaleMiddle AgedNeoplasm Recurrence, LocalPlacebo EffectRituximabTreatment OutcomeLenalidomideRituximabLenalidomideRelapsed/refractory iNHLRituximab

Identifiers

PMID31858429
OpenAlexW2995841997

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.